Search results for: 'NGS Study'

30 Jun 2023  |  Global  |  Market Research

Next-generation Sequencing Informatics, Forecast to 2027

Development of Genomics and Precision Medicine Supported by Artificial Intelligence and Cloud Computing to Transform the Field

Infographics

×

With the democratization of next-generation sequencing (NGS) technology and continual decline in sequencing costs, its application areas have expanded, leading to increased demand for NGS informatics solutions in different environments. The advances in NGS technology are leading to market growth and will likely boost its demand with the incorporati...

NGS library preparation incorporates processing steps that convert genomic DNA or RNA into an appropriate format for the selected sequencing technology. The workflow starts with isolating nucleic acids, fragmented, end-repaired, and connected to adapters using methods like ligation or tagmentation. Sequencing applications incorporate whole genome, ...

08 Nov 2024  |  Global  |  Market Research

Analysis of the Clinical Next-generation Sequencing Sector, Global, 2024-2030

Continued Investment in AI is Driving Transformational Growth by Accelerating Information Solutions Development

Infographics

×

This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. ...

03 Feb 2021  |  North America  |  Market Research

Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-generation Sequencing (NGS) Market

Next-generation Blockchain-Powered Genomic Data Marketplaces are Creating New Growth Opportunities

Infographics

×

2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains unconq...

29 Apr 2016  |  Global  |  Market Research

Global Life Science Instrumentation Market, Forecast to 2020

Innovative Next-generation Sequencing (NGS) Technology to Fuel Growth

Infographics

×

The global life science instrumentation market recorded revenue of $4.05 billion in 2015; it is expected to grow at a Cumulative Annual Growth Rate (CAGR) of 7.6% from 2015 to 2020. Next-generation Sequencing (NGS) instruments has outpaced other research instruments due to reduced sequencing costs. Thermo Fisher Scientific, Agilent Technologies, an...

Sequencing technologies have evolved over the years to harness the value of the human genome and dive deep into DNA and RNA sequences which offer immense knowledge of human biology. From Sanger sequencing to next-generation sequencing, technologies and chemistries have improved/advanced to reduce costs and ensure faster timelines. NGS has integrate...

The molecular diagnostics industry is undergoing consolidation, requiring capital investment and faster regulatory pathways to accelerate clinical adoption. Major diagnostics and life sciences companies are acquiring proprietary testing platforms to strengthen positions in precision oncology and blood-based diagnostics. AI-enabled genomic workflow ...

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinica...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...